Amgen, Inc. (AMGN) Stake Lowered by Viking Fund Management LLC
Viking Fund Management LLC trimmed its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 39.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,500 shares of the medical research company’s stock after selling 5,500 shares during the period. Viking Fund Management LLC’s holdings in Amgen were worth $1,585,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Janus Henderson Group PLC raised its stake in shares of Amgen by 3,664.7% during the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after purchasing an additional 3,601,087 shares during the period. FMR LLC raised its stake in shares of Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after purchasing an additional 2,587,041 shares during the period. Renaissance Technologies LLC raised its stake in shares of Amgen by 40.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after purchasing an additional 986,700 shares during the period. BlackRock Inc. raised its stake in shares of Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after purchasing an additional 909,689 shares during the period. Finally, Nordea Investment Management AB raised its stake in shares of Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after purchasing an additional 806,119 shares during the period. Institutional investors own 78.62% of the company’s stock.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Insiders have sold a total of 8,575 shares of company stock valued at $1,509,339 in the last ninety days. Insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company’s quarterly revenue was down .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.02 EPS. equities research analysts expect that Amgen, Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen declared that its board has authorized a share buyback plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is presently 41.63%.
A number of equities research analysts recently issued reports on AMGN shares. Oppenheimer restated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research note on Friday, October 6th. Mizuho restated a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research note on Friday, October 6th. Cann restated a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Bank of America boosted their price objective on Amgen to $210.00 and gave the company a “buy” rating in a research note on Thursday, October 5th. Finally, Jefferies Group restated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $190.22.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/amgen-inc-amgn-stake-lowered-by-viking-fund-management-llc/1772207.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.